Clinical Trial

A Clinical Trial With KJ103 in Anti-GBM Disease

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 13, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
An open-label, single-arm Phase II study to evaluate the preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of KJ103 in patients with anti-GBM disease.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-18.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-06-10
Trial Details
NCT Number NCT06607016
Lead Sponsor Shanghai Bao Pharmaceuticals Co., Ltd.
Conditions Anti-Glomerular Basement Membrane Disease
Enrollment 12 participants
Start Date 2024-10-21
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2025-06-13